Skip to main content

AMA Announces New CPT Code for Johnson & Johnson's COVID-19 Vaccine

Analysis  |  By Revenue Cycle Advisor  
   January 25, 2021

The AMA also created a new HCPCS Level II code for the vaccine's administration.

A version of this article was first published January 25, 2021, by HCPro's Revenue Cycle Advisor, a sibling publication to HealthLeaders.

The American Medical Association (AMA) recently added a new CPT code that will be used to report a COVID-19 vaccine candidate under development by Janssen Pharmaceutica, a division of Johnson & Johnson.

The new CPT code is:

  • 91303, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use

The AMA also created a new HCPCS Level II code for the vaccine’s administration:

  • 0031A, immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, DNA, spike protein, Ad26 vector, preservative free, 5x1010 viral particles/0.5 mL dosage, single dose

These codes will go into effect when the Food and Drug Administration approves the vaccine candidate or grants it emergency use authorization, according to the AMA.

A complete list of CPT/HCPCS codes for COVID-19 vaccines and associated payment allowances is available here


Revenue Cycle Advisor combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule and regulatory updates thoroughly. Learn more.

Photo credit: Brazil, São Paulo, October 12 2020: Silhouette of scientist hand holding injection with covid-19 vaccine Johnson & Johnson x close-up of the logo Johnson & Johnson / Editorial credit: /

Get the latest on healthcare leadership in your inbox.